Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 3—March 2011

Dispatch

Laboratory-based Surveillance of Extensively Drug-Resistant Tuberculosis, China

Yunfeng Deng, Yan Wang, Junling Wang, Hui Jing, Chunbao Yu, Haiying Wang, Zhimin Liu, Edward A. Graviss, and Xin MaComments to Author 
Author affiliations: Author affiliations: Shandong Provincial Chest Hospital, Jinan, People’s Republic of China (Y. Deng, Y. Wang, J. Wang, H. Jing, C. Yu, H. Wang, Z. Liu, X. Ma); The Methodist Hospital Research Institute, Houston, Texas, USA (E.A. Graviss, X. Ma)

Main Article

Table 1

First- and second-line drug resistance of 989 clinical Mycobacterium tuberculosis isolates, People’s Republic of China, November 2004–April 2007*

Drugs* No. isolates Rate, %
Overall first-line drug resistance 319 32.3
INH 187 (44) 18.9 (4.4)
RFP 159 (16) 16.1 (1.6)
EMB 46 (0) 4.7 (0)
SM
238 (78)
24.1 (7.9)
MDR, overall 107 10.8
INH + RFP 16 1.6
INH + RFP + EMB 2 0.2
INH + RFP + SM 58 5.9
INH + RFP + EMB + SM
31
3.1
Overall second-line drug resistance 189 19.1
FQ 162 (103) 16.4 (10.4)
AMK 32 (0) 3.2 (0)
CPM 56 (14) 5.7 (1.4)
PAS
37 (6)
3.7 (0.6)
Second-line drug polyresistance 66 6.6
FQ + AMK 8 0.8
FQ + AMK + CPM 9 0.9
FQ + AMK + PAS 4 0.4
FQ + AMK + CPM + PAS 6 0.6
FQ + CPM 15 1.5
FQ + PAS 10 1.0
FQ + CPM + PAS 7 0.7
AMK + CPM 3 0.3
AMK + PAS 1 0.1
AMK + CPM + PAS 1 0.1
CPM + PAS 2 0.2

*Numbers and rates of mono–first- and -second–line drug-resistant strains shown in parentheses. INH, isoniazid; RFP, rifampin;, EMB, ethambutol; SM, streptomycin; MDR, multidrug-resistant; FQ, fluoroquinolines (specifically ciprofloxacin and levofloxacin); AMK, amikacin; CPM, capreomycin; PAS, para-aminosalicylic acid.

Main Article

TOP